# A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06480240/  
OnCo record `nct06480240` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of OBI-992 in advanced solid tumours, run by OBI Pharma, Inc, active and no longer recruiting.

## Summary

A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06480240 by OBI Pharma, Inc, with 117 participants enrolled, started 2024-06-12 and due to reach its primary completion in 2027-06. Interventions recorded: OBI-992.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06480240
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-992 in Subjects With Advanced Solid Tumors
- Sponsor: OBI Pharma, Inc
- Enrolled: 117

## Sources

- ClinicalTrials.gov NCT06480240: https://clinicaltrials.gov/study/NCT06480240

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [OBI-992](https://onco.cc/drugs/obi-992/)

---
JSON: https://onco.cc/api/v1/entities/nct06480240.json